What the results of Wegovy's longest clinical trial yet show about weight loss, side effects and heart protection

New analyses of a weight-loss drug called Wegovy have revealed insights into its effectiveness, long-term sustainability of weight loss, and safety over a four-year period. The analyses, based on the Select trial, which demonstrated Wegovy’s ability to reduce heart risk, suggest that the medication may have heart benefits beyond just weight loss. These findings raise questions about the appropriate use and insurance coverage of drugs in this class. Over 25,000 people in the US are starting Wegovy each week, and a poll indicates that around 6% of respondents are using drugs in this class, translating to over 15 million Americans.